{
    "clinical_study": {
        "@rank": "142986", 
        "arm_group": {
            "arm_group_label": "Dose-escalation", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This open-label, Phase I study will evaluate the safety, tolerability, and pharm acokinetics\n      of increasing doses of GDC-0853 in patients with relapsed or refract ory B-cell\n      non-Hodgkin's lymphoma or chronic lymphocytic leukemia. In a dose-exp ansion part, GDC-0853\n      will be assessed in subsets of patients."
        }, 
        "brief_title": "A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.", 
        "completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Lymphocytic Leukemia, Chronic, Lymphoma, B-Cell", 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma", 
                "Lymphoma, B-Cell", 
                "Chronic Disease"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age >/= 18 years\n\n          -  ECOG score of 0-1\n\n          -  One of the following histologically-documented hematologic malignancies for which no\n             effective standard therapy exists: indolent non Hodgkin's lymphoma (NHL), follicular\n             lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), or\n             chronic lymphocytic leukemia (CLL)\n\n          -  At least one site of disease that, as seen on CT scan, is > 1.5 cm in the greatest\n             transverse diameter or > 1.0 cm in short axis diameter (except for patients with CLL)\n\n          -  An available tumor specimen\n\n          -  Adequate hematologic and organ function\n\n          -  For female patients of childbearing potential and male patients with partners of\n             childbearing potential, use of effective contraceptive(s) as defined by protocol for\n             the duration of the study\n\n        Exclusion Criteria:\n\n          -  Life expectancy < 12 weeks\n\n          -  < 3 weeks since the last anti-tumor therapy, including chemotherapy, biologic,\n             experimental, hormonal or radiotherapy (with the exception of leuprolide or similar\n             medications for prostate cancer)\n\n          -  Recent major surgical procedure or traumatic injury, or unhealed incisions or wounds\n\n          -  Active infection requiring IV antibiotics\n\n          -  Clinically significant history of liver disease, including viral or other hepatitis,\n             current alcohol abuse, or cirrhosis.\n\n          -  Primary CNS malignancy or untreated/active CNS metastases (progressing or requiring\n             anticonvulsants or corticosteroids for symptomatic control)\n\n          -  History of other malignancy within 5 years prior to screening, except for\n             appropriately treated carcinoma in situ of the cervix, non-melanoma skin cancer,\n             Stage I uterine cancer, or other cancers with a similar outcome\n\n          -  Cardiovascular dysfunction, including ventricular dysrhythmias or risk factors for\n             ventricular dysrhythmias\n\n          -  Pregnancy, or lactation\n\n          -  Any other diseases that contraindicates the use of an investigational drug or that\n             may affect the interpretation of the results or render the patient at high risk from\n             treatment complications"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "121", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01991184", 
            "org_study_id": "GO29089"
        }, 
        "intervention": {
            "arm_group_label": "Dose-escalation", 
            "description": "Multiple escalating doses", 
            "intervention_name": "GDC-0853", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 2, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94305-5820"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43212"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Eugene", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97401-8122"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97201"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98109"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nedlands", 
                        "country": "Australia", 
                        "state": "Western Australia", 
                        "zip": "6009"
                    }
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "AN OPEN-LABEL, PHASE I, DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF GDC-0853 IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN'S LYMPHOMA AND CHRONIC LYMPHOCYTIC LEUKEMIA", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: GO29089 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Genentech", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Safety: Incidence of dose-limiting toxicities (DLTs) of GDC-0853", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 1 year"
            }, 
            {
                "measure": "Safety: Maximum tolerated dose (MTD) of GDC-0853", 
                "safety_issue": "Yes", 
                "time_frame": "Approximately 1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01991184"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Pharmacokinetics: Area under the concentration-time curve (AUC) of GDC-0853", 
                "safety_issue": "No", 
                "time_frame": "35 days"
            }, 
            {
                "measure": "Pharmacokinetics: Maximum concentration (Cmax) of GDC-0853", 
                "safety_issue": "No", 
                "time_frame": "35 days"
            }, 
            {
                "measure": "Objective response to GDC-0853", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }, 
            {
                "measure": "Progression-free survival", 
                "safety_issue": "No", 
                "time_frame": "Approximately 2 years"
            }
        ], 
        "source": "Genentech", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Genentech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}